

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

Prot. n°			Patologia	Titolo	Osservazionale (O)/ Sperimentale (S)	profit (P)/ no profit (NP)
220	/	19	NEUROENDOCRINO	ENETS - REGISTRY	O	NP
240	/	19	NET	Studio di fase II finalizzato a valutare il profilo di sicurezza e di attività di cabozantinib in combinazione a lanreotide in tumori neuroendocrini (NET) gastroenteropancreatici (GEP) e toracici (LOLA trial).	S	NP
299	/	20	NET	InterNaTional rEgistry oN Sars-cov-2 posltiVe nEuroendocrine neoplasm patients	O	NP
159	/	22	NET	Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial	S	NP
130	/	20	NET	Identificazione di predittori molecolari di risposta alla terapia radiorecettoriale in pazienti con GEP-NETs	O	NP
272	/	20	NET	Financial Toxicity and Patient-Reported Outcomes in Italian Patients affected by Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN)	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

158	/	23	NET	Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (PANDORA)	S	NP
61	/	23	NET	Studio italiano multicentrico di fase II con TemozolomideMetronomica in pazienti “fragili”con neoplasia neuroendocrina avanzata(NEN): studio MeTe	S	NP
128	/	24	EPSCC	AGNOSTIC THERAPY IN A PHASE II, MULTICENTER, SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB (MEDI 4736) IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (EPSCC) – DURVASCC TRIAL	S	NP
177	/	14	PANCREAS-VIE BILIARI	Identificazione delle cellule tumorali circolanti e dei livelli di ctDNA nel sangue dei pazienti affetti	O	NP
113	/	21	PANCREAS-VIE BILIARI	STUDIO OSSERVAZIONALE SULL'IMPATTO PROGNOSTICO/PREDITTIVO DELLE ALTERAZIONI DEI GENI DEL DNA REPAIR SUI TUMORI BILIOPANCREATICI	O	NP
115	/	23	PANCREAS-VIE BILIARI	An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	S	NP
119	/	23	PANCREAS-VIE BILIARI	A phase II/III randomized clinical trial of CisPlatin pIUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patlents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

71	/	24	PANCREAS-VIE BILIARI	TT420C2308_A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)	S	P
106	/	24	PANCREAS-VIE BILIARI	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)	S	P
20	/	24	PANCREAS-VIE BILIARI	liver-R: An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers	O	P
04	/	15	GASTRO-ENTERICO	Studio prospettico per la determinazione del profilo molecolare di resistenza alle "terapie target" in pazienti con tumori solidi – protocollo profiling-CANDIOLO	O	NP
117	/	15	GASTRO-ENTERICO	Valutazione esplorativa di nuovi potenziali fattori prognostici in pazienti affetti da carcinomi gastrointestinali	O	NP
120	/	15	GASTRO-ENTERICO	Studio multicentrico traslazionale per la determinazione del profilo genomico dei carcinomi a primitività sconosciuta (CUP). De braud	O	NP
205	/	17	GASTRO-ENTERICO	Studio AMNESIA: Studio italiano osservazionale multicentrico sui meccanismi molecolari di resistenza al Trastuzumab in tumori dello stomaco o della giunzione gastro-esofagea (GGE) HER-2 positivi	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

136	/	19	COLON	A master protocol empowering Precision Research in Colorectal Cancer. NO -PROFIT	O	NP
204	/	20	ESOFAGO	RANDOMIZED PHASE II STUDY OF PANITUMUMAB RECHALLENGE FOLLOWED BY REGORAFENIB versus THE REVERSE SEQUENCE IN RAS AND BRAF WILD-TYPE CHEMOREFRACTORY METASTATIC COLORECTAL CANCER PATIENTS	S	NP
151	/	20	COLON	Studio di Fase 1b con la combinazione 5-fluorouracile, leucovorin, irinotecano e temozolomide (FLIRT) in associazione a bevacizumab come trattamento di prima linea in pazienti con carcinoma del colon-retto metastatico con stabilità dei microsatelliti e silenziamento di MGMT	S	NP
289	/	20	COLON	A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03	S	P
149	/	21	COLON	Studio di fase III randomizzato volto a valutare l'efficacia e la sicurezza di Lenvatinib (E7080/MK-7902) più Pembrolizumab (MK-3475) più chemioterapia rispetto alla terapia assistenziale standard come trattamento di prima linea nei partecipanti con adenocarcinoma gastroesofageoavanzato/metastatico (LEAP-015)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

65	/	21	GASTRO-ENTERICO	“Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Blospy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB (LIBImAb Study)”	S	NP
188	/	21	COLON	“Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial”	S	NP
201	/	21	GASTRICO	AN OPEN-LABEL, SINGLE-ARM, PHASE IB/IIA TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE EP4 RECEPTOR ANTAGONIST CR6086 IN COMBINATION WITH THE PD-1 INHIBITOR BALSTILIMAB (AGEN2034), IN PATIENTS WITH PRETREATED MISMATCH-REPAIR-PROFICIENT AND MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER.”	S	P
201	/	21	PANCREAS	AN OPEN-LABEL, SINGLE-ARM, PHASE IB/IIA TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE EP4 RECEPTOR ANTAGONIST CR6086 IN COMBINATION WITH THE PD-1 INHIBITOR BALSTILIMAB (AGEN2034), IN PATIENTS WITH PRETREATED MISMATCH-REPAIR-PROFICIENT AND MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER.”	S	P
173	/	21	ESOFAGO	Protocol Title:A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

216	/	21	COLON	Studio prospettico per l'investigazione della biologia tumorale e dei fattori di resistenza alle terapie mediante biopsia liquida e patient derived organoids (PDO) in pazienti con tumori del tratto gastroenterico, bilio-pancreatico, tumori neuroendocrini e carcinomi a cellule di Merkel”	O	NP
140	/	21	GASTRO-ENTERICO	ItaLynch: mainstreaming the diagnosis of Lynch Syndrome	O	NP
03	/	21	GASTRO-ENTERICO	Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study	S	NP
231	/	21	GASTRO-ENTERICO	Studio osservazionale sulle caratteristiche cliniche ed anatomopatologiche e sugli outcome dei pazienti affetti da carcinomi gastrointestinali e neoplasie neuroendocrine afferenti all'Istituto Nazionale dei Tumori di Milano.	O	NP
181	/	22	GASTRO-ENTERICO	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

137	/	22	COLON	CAVE-2 (Cetuximab-AVElumab) mCRC: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients.	S	P
119	/	22	COLON	EXPLOITING CIRCULATING TUMOUR DNA TO INTENSIFY THE POST-OPERATIVE TREATMENT OF STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS WITH ADJUVANT FOLFOXIRI AND/OR POST-ADJUVANT TRIFLURIDINE/TIPIRACIL	S	NP
04	/	23	COLON	A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer_ ORIGAMI	S	P
136	/	22	ESOFAGO	A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B	S	P
118	/	23	COLON	WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE TARGETED TREATMENTS IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

27	/	23	COLON	An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer - SGNTUC-029 (MOUNTAINEER-03)	S	P
233	/	23	GASTRICO	Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNlmal residual disease in liquid biopsy after preoperative chemoTherapy and radical surgerY: the TRINITY study	O/S	P
264	/	21	COLON	A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	S	P
13	/	24	COLON	Phase II study evaluating Holmium-166 TARE followed by maintenance Therapy in liver limited unresectable colorectal cancer patients after first-line chemotherapy and target agents: The HAITI study	S	NP
36	/	24	GASTRICO	MK-9999-02A Substudy: A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

38	/	24	GASTRICO	A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)	S	P
187	/	24	COLON	BRICKET_SINGLE ARM PHASE II STUDY OF ctDNA-GUIDED ENCORAFENIB PLUS CETUXIMAB RETREATMENT IN PATIENTS WITH BRAFV600E MUTATED mCRC	S	NP
46	/	24	GASTRICO	CL1-95029-002_Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti- NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSIH/dMMR gastroesophageal junction /gastric cancer	S	P
188	/	24	COLON	Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)".	S	NP
71	/	18	GU	indagare fattori predittivi di risposta in pazienti affetti da carcinoma renale metastatico (mRCC) trattati con Nivolumab (studio I-RENE)	O	NP
147	/	18	GU	BIORENE (No profit osservazionale BIOLOGICO prospettico) Studio prospettico traslazionale volto ad indagare fattori prognostici e predittivi di risposta o resistenza ai trattamenti in pazienti affetti da carcinoma renale metastatico (mRCC)	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

107	/	18	GU	ACACIA (No profit con farmaco) Studio multicentrico, randomizzato, in aperto di fase III volto a valutare l'attività di chemioterapia adiuvante versus osservazione/mitotane dopo chirurgia di prima linea in pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva	S	NP
228	/	19	GU	RI-nivo- Studio osservazionale retrospettivo sulla sicurezza di Nivolumab nei Pazienti con Carcinoma Renale Metastatico ed Insufficienza Renale	O	NP
175	/	20	GU	Osteonecrosi della mandibola in pazienti affetti da carcinoma renale con metastasi ossee. Studio retrospettivo multicentrico (studio REBONE)	O	NP
89	/	21	GU	KATY:Studio Osservazionale prospettico biologico/retrospetivo (raccolta campioni biologici)	O	NP
220	/	22	GU	RENE MULTIOMICAAproccio integrato multiomico nel carcinoma renale metastatico	O	NP
206	/	22	GU	Approccio multimodale in pazienti con carcinoma prostatico metastatico ormono sensibile. Studio pragmatico randomizzato con Apalutamide e trattamento locale. (APPROACH Trial)	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

67	/	23	GU	Studio di fase I/IIa, a bracci multipli, in aperto per valutare la sicurezza, la tollerabilità, la farmacocinetica, la farmacodinamica e l'efficacia preliminare di AZD5305 in combinazione con agenti ormonali di nuova generazione in pazienti con carcinoma prostatico metastatico (PETRANHA)	S	p
12	/	21	GU	carcinoma dei dotti collettori di Bellini: analisi biologica e terapia personalizzata (CICERONE)	O	NP
280	/	20	GU	valutazione della cardio tossicità e ipertensione nei pazienti con carcinoma prostatico castrazione resistenti non metastatici APA_CARDIO1	O	NP
66	/	23	GU	AXIN Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response	S	NP
70	/	23	GU	Studio di fase II: Efficacia del trattamento PERioperatorio con Pembrolizumab nei pazienti con metastasi resecabili di carcinoma renale (Studio PE-PE).	S	NP
193	/	23	GU	A Phase II Open-Label Study of Sacituzumab Govitecan in UnresectableLocally Advanced/Metastatic Urothelial Cancer-Immu-132-06	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

69	/	23	GU	a phase 1/2 randomized, umbrella study to evaluate the safety and efficacy of pembrolizumab plus enfortumab vedotin (EV) in combination with investigational agents versus pembrolizumab plus EV, as first-line treatment for participants with advanced urothelial carcinoma (KEYMAKER -U04): substudy 04B	S	P
45	/	16	GU	MK-3475-057 A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy	S	p
179	/	18	GU	mk676- STUDIO CLINICO DI FASE 3, RANDOMIZZATO, CONTROLLATO CON PRODOTTO DI CONFRONTO PER STUDIARE L'EFFICACIA E LA SICUREZZA DI PEMBROLIZUMAB (MK-3475) IN COMBINAZIONE CON BACILLO DI CALMETTE - GUERIN (BCG) IN SOGGETTI AFFETTI DA TUMORE DELLA VESCICA NON-MUSCOLO INVASIVO AD ALTO RISCHIO (HR NMIBC) CHE E' PERSISTENTE O RICORRENTE DOPO INDUZIONE CON BCG.	S	NP
180	/	18	GU	Cabozantinib plus durvalumab (Medi 4736) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial-ARCADIA	S	NP
71	/	23	GU	A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (Imvigor_BO42843)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

136	/	23	GU	SATURNO - Registro Italiano prospettico e multicentrico sul carcinoma uroteliale localmente avanzato-metastatico	O	NP
279	/	23	GU	MK-5684-003 A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	S	P
277	/	23	GU	MK-5684-004 A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	S	P
278	/	23	GU	V940-005: A Phase 2, Randomized, Double-blind, Placebo- and Active-comparatorcontrolled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection	S	P
45	/	24	GU	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

43	/	24	GU	Enfortumab Vedotin for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Chemotherapy and Immunotherapy: A Multicenter, Non-interventional Study in Italy (EVIDENCE)	O	P
02	/	24	GU	CatalYm: A MULTI-CENTER PHASE 2 STUDY OF NEOADJUVANT IMMUNOTHERAPY IN COMBINATION WITH THE ANTI-GDF-15 ANTIBODY VISUGROMAB (CTL-002) FOR THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER	S	P
44	/	24	GU	V940-004: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma	S	P
66	/	24	GU	Identificazione e valutazione di biomarkers immuno-relati in pazienti con carcinoma prostatico avanzato: dall'animale all'uomo, analisi traslazionale dello studio PROPARCY.	O	NP
23	/	18	POLMONE	NO-PROFIT_Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME Studio RELEVANT.	S/O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

196	/	19	POLMONE	TRIDENT - 1A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	S	P
37	/	18	POLMONE	MILES 5 : A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC.	S	NP
22	/	15	POLMONE	APOLLO	O	NP
147	/	22	POLMONE	Progetto europeo per l'implementazione di cure mediche personalizzate basate sull'intelligenza artificiale (AI) nei pazienti con tumore al polmone_ I3LUNG	O	NP
128	/	22	POLMONE	APOLLO 11, CONSORZIO DI CENTRI COINVOLTI NELLA CURA DI PAZIENTI CON TUMORE POLMONARE TRATTATI CON TERAPIE INNOVATIVE: INTEGRAZIONE DI DATI REAL WORLD E RICERCA TRASLAZIONALE	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

196	/	22	POLMONE	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	S	P
65	/	22	POLMONE	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC	S	P
23	/	23	POLMONE	An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	S	P
58	/	23	POLMONE	A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy	S	P
122	/	23	POLMONE	Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

32	/	23	POLMONE	Disease Registry on patients with advance non-small cell lung canecr (NSCLC) harboring METex14 skipping alterations_ MOMENT (Met nOn sMall Cell caNcer regisTry)	O	NP
28	/	23	POLMONE	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	S	P
198	/	23	POLMONE	Randomized, Open-label, Multicenter Phase 3 Trial of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3_CA127-1030)	S	P
157	/	23	POLMONE	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreak K 202)	S	P
287	/	23	POLMONE	Bone Marrow-on-Chip: un sensore di recidiva precoce nel tumore del polmone (BuonMarrow) Studio osservazionale prospettico/retrospettico per valutare il ruolo delle cellule staminali mesenchimali del midollo osseo (BM-MSCs) come sensori precoci di recidiva tumorale, in pazienti sottoposti a chirurgia e a chemioterapia neo/adjuvante con o senza immunoterapia per carcinoma polmonare non a piccole cellule, attraverso l'utilizzo di un modello in vitro di midollo osseo artificiale (BM-on-chip).	O	NP
249	/	23	POLMONE	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

251	/	23	POLMONE	A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer	S	P
270	/	23	POLMONE	SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression	S	P
46	/	23	POLMONE	BO44426_A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF DIVARASIB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION	S	P
247	/	23	POLMONE	MK2870-007_A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%	S	P
121	/	24	POLMONE	TYME: TYmic Malignancies nEtworK per l'integrazione di dati real world e per la caratterizzazione biologica dei tumori epiteliali del timo	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

186	/	20	MELANOMA	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A	S	P
71	/	21	MELANOMA	Studio osservazionale, retrospettivo-prospettico volto all'individuazione di nuovi fattori prognostici e predittivi in pazienti affetti da melanoma sottoposti a terapia antitumorale	O	NP
15	/	22	MELANOMA	Registro Clinico Nazionale sul Melanoma II	O	NP
109	/	23	MELANOMA	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)	S	P
155	/	18	TUMORI SOLIDI	“Studio di fase 1 con aumento progressivo della dose e ampliamento delle coorti, per la valutazione di TSR-042, un anticorpo monoclonale anti-PD-1, in pazienti affetti da tumori solidi in stadio avanzato” - N. protocollo: 4010-01-001	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

193	/	21	TUMORI SOLIDI	A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER	S	P
191	/	21	TUMORI SOLIDI	Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor2 Overexpression (HER2+)(DESTINY-Lung03)	S	P
5	/	22	TUMORI SOLIDI	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	S	P
60	/	22	TUMORI SOLIDI	A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TALETRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC ROS1 POSITIVE NSCLC AND OTHER SOLID TUMORS	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

114	/	22	TUMORI SOLIDI	A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors	S	P
52	/	23	TUMORI SOLIDI	A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.	S	P
114	/	23	TUMORI SOLIDI	A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	S	P
112	/	23	TUMORI SOLIDI	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

66	/	21	TUMORI SOLIDI	TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU(TAPISTRY)PHASE IIPLATFORM TRIAL	S	P
110	/	23	TUMORI SOLIDI	A Phase I, open label, multi-center study of KFA115 as a single agent and in combination with Tislelizumab in patient with select advanced cancer	S	P
215	/	23	TUMORI SOLIDI	An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors	S	P
47	/	24	TUMORI SOLIDI	IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination with Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies	S	P
196	/	23	TUMORI SOLIDI	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	S	P
19	/	24	TUMORI SOLIDI	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNAACLE)	S	P
54	/	23	TUMORI SOLIDI	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

192	/	21	TUMORI SOLIDI	Basket ofBaskets: A Modular, Open-label, Phase II, Multicentre Study ToEvaluateTargeted Agents in Molecularly Selected PopulationsWith Advanced Solid Tumours.	S	NP
196	/	20	C.MAMMARIO	A Master Protocol Empowering Mechanobiology TranslationalResearch in BreastCancer	O	NP
221	/	21	C.MAMMARIO	EPIK-B5: Studio di Fase III, randomizzato, in doppio cieco, controllato versus placebo, conalpelisib (BYL719) in associazione a fulvestrant negli uomini e nelle donne in post-menopausa con carcinoma mammario in stadio avanzato HR-positivo, HER2-negativo con mutazione PIK3CA, che ha manifestato progressione durante o dopo inibitore dell'aromatasi e inibitore di CDK4/6	S	P
108	/	22	C.MAMMARIO	NONINTERVENTIONAL, MULTICENTRE, PROSPECTIVE, COHORT STUDY ASSESSING THE QUALITY OF LIFE AND HORMONAL LEVELS IN PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE EARLY BREAST CANCER IN ITALY – ROSE STUDY NONINTERVENTIONAL, MULTICENTRE, PROSPECTIVE, COHORT STUDY ASSESSING THE QUALITY OF LIFE AND HORMONAL LEVELS IN PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE EARLY BREAST CANCER IN ITALY – ROSE STUDY	O	NP
214	/	22	C.MAMMARIO	Targeting triple negative BREAst cancer metabolism with a combination of chemoimmunotherapy and a FASTing-like approach in the preoperative setting: the BREAKFAST 2 trial	S	NP
193	/	22	C.MAMMARIO	RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

207	/	22	DIETA	FASTing-like approach to improve the efficacy of maintenance IMMUnotherapy in Extensive-stage small cell lung cancer patients not progressing on chemoimmunotherapy induction: the FASTIMMUNE trial	O (intervestico no IMP)	NP
254	/	23	C.MAMMARIO	A MULTI COHORT TRANSLATIONAL RESEARCH STUDY TO INVESTIGATE MECHANISMS OF RESISTANCE TO BREAST CANCER THERAPIES_ WO44977 REMERGE	O (intervestico no IMP)	P
231	/	23	C.MAMMARIO	A Phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy	S	P
223	/	23	C.MAMMARIO	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGOà VERSUS PLACEBO IN COMBINATION WITH PHESGOà AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA-MUTATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	S	P
269	/	23	C.MAMMARIO	A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	S	P
148	/	24	C.MAMMARIO	A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery	S	P
84	/	24	C.MAMMARIO	A National Retrospective Observational Study Characterizing Utilization and Effectiveness Outcomes in Patients with Metastatic Breast Cancer Receiving Abemaciclib_ REAL	O	NP